Boryung Launches 'Dasakin Tab.' for Chronic Myeloid Leukemia Treatment

The First Domestic Generic Anti-Cancer Drug Containing Dasatinib

Boryung Corp. announced on May 14 that it has launched 'Dasakin Tab. (active ingredient: dasatinib)', a treatment for chronic myeloid leukemia.

Dasakin is the first domestic generic drug containing dasatinib, and is a second-generation targeted anti-cancer agent that selectively inhibits the BCR-ABL fusion protein (a tyrosine kinase) responsible for cancer cell proliferation. It is mainly used for the treatment of chronic myeloid leukemia (CML), a type of blood cancer.

The product is available in a total of five dosages: 20mg, 50mg, 70mg, 80mg, and 100mg. In particular, it offers a differentiated treatment option and greater convenience for patients by being the only product in Korea to provide the 70mg dosage. Additionally, with a more economical price compared to the original, it is expected to help reduce the financial burden for leukemia patients who require long-term treatment.

Following the first-generation targeted anti-cancer drug Glima (active ingredient: imatinib), Boryung has now introduced the second-generation treatment, Dasakin, thereby establishing a comprehensive range of therapeutic options tailored to the different stages of CML progression. Patients who experience resistance or side effects to first-generation therapies can now receive continuous treatment with Dasakin.

In March, Boryung also signed a licensing-in agreement for the new blood cancer drug 'Xpovio' with the Chinese pharmaceutical company Antengene, further strengthening its expertise in the hematologic malignancy business. Currently, Boryung offers a broad lineup of nine products for blood cancer—including Dasakin, Glima (imatinib), Velkin (bortezomib), Revlekin (lenalidomide), Formalikin (pomalidomide), Xpovio (selinexor), Debikin (decitabine), Bijadakin (azacitidine), and Vencod (bendamustine)—and, backed by a specialized organization, provides solutions covering the entire treatment cycle from initial diagnosis to relapse and refractory stages.

Baek Minseong, Head of BD & Marketing Division at Boryung, stated, "We have launched Dasakin with the goal of ensuring treatment continuity and improving the quality of life for leukemia patients," adding, "We will do our utmost to secure early market entry and build trust with healthcare professionals and patients through our expertise in hematologic malignancies and evidence-based sales and marketing."

This content was produced with the assistance of AI translation services.